Effective September 26, 2023, NRG Oncology-RTOG 1308, a phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for patients with inoperable stage II-IIIB non-small cell lung cancer (NSCLC) has met its accrual target. The trial, one of several NRG Oncology ongoing clinical trials across various malignancies within the National Clinical Trials Network (NCTN) that compare photon versus proton radiation therapy techniques, is the first phase III head-to-head comparison of these radiation methods to meet accrual.

https://www.miragenews.com/phase-iii-trial-comparing-photon-vs-proton-1096573/

#miragenews